.
MergerLinks Header Logo

Announced

Vertex to acquire ViaCyte for $320m.

Financials

Edit Data
Transaction Value£265m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Biotechnology

Majority

Domestic

Single Bidder

Friendly

biotechnology company

Pending

Acquisition

Private

Synopsis

Edit

Vertex, an American biopharmaceutical company, agreed to acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, for $320m. “ViaCyte’s commitment to finding a functional cure for T1D is shared by Vertex, and this acquisition will allow Vertex to deploy ViaCyte’s tools, technologies and assets toward the development of Vertex’s multiple cell replacement therapy approaches designed to reduce the burden of millions of people living with T1D worldwide,” Michael Yang, ViaCyte President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US